Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
April 12, 2012
Will the addition of olaparib maintenance therapy prolong PFS in platinum-sensitive recurrent ovarian cancer that responded to conventional chemotherapy?
Olaparib 400mg PO BID
Recurrent, high-grade serous ovarian cancer
2+ platinum-containing treatment regimens
Olaparib vs. Placebo:
median treatment duration ~7 months
median PFS: 8.4 vs. 4.8 months (SS)
AEs higher with olaparib: nausea, fatigue, vomiting, & anemia
Olaparib maintenance prolonged PFS in women with recurrent platinum-sensitive ovarian cancer regardless of BRCA status with manageable toxicity.